Topical TCA and SSRI Treatment for Radiation Dermatitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for radiation dermatitis, a common side effect of radiation therapy, are inadequate in prevention and management, with existing medications offering little to no protection against skin damage and pigmentation changes, and there is a significant unmet need for effective preventive or therapeutic options for millions of patients.
Innovation Solution
Topical or oral administration of tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), such as amitriptyline and sertraline, in various dosage forms to prevent, treat, or ameliorate radiation dermatitis, either alone or in combination with other active ingredients like antioxidants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If topical corticosteroids are used, then inflammation may be reduced, but they have little to no effect on pigmentation changes and do not prevent radiation dermatitis
Solution Approach 1:
The patent changes the chemical parameter of the treatment by replacing corticosteroids with TCAs and SSRIs, which have different mechanisms of action. These antidepressants affect neurotransmitter levels and have been shown to prevent radiation-induced skin damage, thereby improving both prevention capability and treatment effectiveness simultaneously
2Object-affected harmful factors
If aloe vera and topical Vitamin C are applied, then skin care is provided, but no improvement in irradiated breast tissue results is achieved
Solution Approach 1:
The patent changes the active ingredient parameter from conventional skin care agents (aloe vera, Vitamin C) to psychotropic medications (TCAs and SSRIs). Clinical evidence shows these antidepressants have radioprotective properties that the traditional skin care agents lack, thereby achieving both skin care and genuine radiation protection
3Object-affected harmful factors
If misoprostol is administered, then radioprotection is achieved in animal studies, but successful results are not obtained in humans
Solution Approach 1:
The patent changes the chemical class of radioprotective agents from prostaglandin analogs (misoprostol) to antidepressants (TCAs and SSRIs). The antidepressants have demonstrated effectiveness in both animal models and human clinical trials, achieving the desired cross-species adaptability that misoprostol failed to achieve
4Ease of operation
If biafine and lipiderm are applied, then skin care is provided, but no radioprotective effect is observed
Solution Approach 1:
The patent changes the functional parameter of the topical agents from purely emollient/protective (biafine, lipiderm) to pharmacologically active (TCAs and SSRIs). The antidepressants provide both skin care benefits and genuine radioprotection through their mechanism of action on cellular processes, achieving dual functionality that the skin care agents alone cannot provide
Data Source
AI summary
A composition comprising at least one TCA or SSRI useful in a method for preventing or treating a skin disorder such as radiation dermatitis, and method of preventing, ameliorating, or treating the skin disorder by administering an effective amount of the TCA, e.g., amitriptyline or the SSRI, e.g., sertraline.